Tenecteplase vs Alteplase for Acute Stroke
Dietrich Jehle, MD, FACEP, RDMS serves as Program Director, Professor, and Chair of the Department of Emergency Medicine at the University of Texas Medical Branch in Galveston, Texas. Dr. Jehle assisted with the development of the Emergency Medicine Residency at Allegheny General Hospital in Pittsburgh, PA in 1982. He relocated... more
Just Published in Annals of Emergency Medicine (May 11, 2023) - four times larger than any prior study comparing TNK (Tenecteplase) and tPA (Alteplase) for Stroke
http://myimageserver.com/fatd/branding/Dietrich_Jehle_Anals_Article.pdf
Conclusion: In our large retrospective multicenter study using real-world evidence from large healthcare organizations, tenecteplase (TNK) for the treatment of acute stroke demonstrated a lower mortality rate, decreased intracranial hemorrhage, and less significant blood loss. The favorable mortality and safety profiles observed in this large study, taken together with previous randomized controlled trial data and operational advantages in rapid dosing and cost-effectiveness, all support the preferential use of tenecteplase in patients with ischemic stroke. [Ann Emerg Med. 2023;-:1-9.]
